Novavax Covid Vaccine Shows 90% Success

Novavax Covid Vaccine Shows 90% Success. The vaccine manufacturer said on Monday that Novavax’s COVID-19 syringes are more than 90% effective against variants of the coronavirus itself. Earlier, the company said in a statement that a large-scale study in the United States added: “Research Involving 29,960 people in 119 locations. Efficacy, safety were evaluated in the United States and Mexico.

The Maryland-based company plans to apply for regulatory approval by the third quarter of 2021. “New data release: Novavax # COVID19 vaccine showed 90% overall effectiveness and 100% moderate to severe disease protection in the Phase 3 PREVENT-19 study” https://www.youtube.com/watch? ://t.co/ lIOiQXxDtDpic.twitter.com / 4ePHxDpziZ-Novavax) (@Novavax) June 14, 2021After that, he is expected to reach 100 million cans per month by the end of the third quarter and 150 million cans per month by the end of the year.

Novavax President and CEO Stanley S. Erk said: “Novavax is now one step closer to addressing key challenges and the continuing need for additional COVID-19 vaccines in global public health.” “Novavax continues to work urgently to complete our regulatory documents. And provide this well-founded vaccine. Although some wealthy countries have made progress in vaccinating their populations, there are still concerns that many poorer countries are still not participating in the global vaccination campaign.

The poorest countries in the world are far behind. In the seven major industrialized countries and other rich countries; in terms of dosage, the imbalance between G7 and the world’s low-income countries determined by the World Bank is 73:1. Stored at extremely low temperatures. The company said that vaccines are stored at 2 -8°C and stable, allowing the use of existing channels in the vaccine supply chain for distribution. At least in theory, this means that injections must be shipped to less-developed countries and it is easier to inject. Sanitation infrastructure.